Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli

J Microbiol Immunol Infect. 2010 Aug;43(4):310-6. doi: 10.1016/S1684-1182(10)60048-5.

Abstract

Background/purpose: The risk factors for production of extended-spectrum beta-lactamases (ESBLs) have rarely been studied for bloodstream infections of Escherichia coli alone. A case-control study was undertaken to identify the risk factors associated with bloodstream infections caused by ESBL producing E. coli.

Methods: From January 1, 2005 to June 30, 2007, all patients with a confirmed diagnosis of bloodstream infection caused by ESBL-producing E. coli were reviewed. Each patient was matched with one control subject who experienced ESBL-negative E. coli bacteremia during the same study period.

Results: Of the 97 patients diagnosed with ESBL-producing E. coli bacteremia, six were excluded owing to incomplete follow-up and missing data. Comparisons were made between 91 patients and their controls. Multivariate analysis identified urinary catheterization [odds ratio (OR) = 6.21, 95% confidence interval (CI) = 1.91-20.25; p = 0.003], prior exposure to antibiotics (OR = 2.93, 95% CI = 1.18-7.30; p = 0.021) and previous treatment with oxyimino-cephalosporins (OR = 5.16, 95% CI = 1.03-25.79; p = 0.046) as independent predictors for bloodstream infection by ESBL-producing E. coli. Conversely, patients classified as having a community-acquired infection were less likely to acquire bacteremia caused by ESBL-producing E. coli than those caused by non-ESBL-producing E. coli (OR = 0.22, 95% CI = 0.09-0.57; p = 0.002).

Conclusion: More judicious use of antimicrobial agents, especially oxyimino-cephalosporins, and avoidance of urinary catheterization may decrease the possibility of ESBL-producing E. coli bacteremia in hospitalized patients.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / epidemiology*
  • Bacteremia / microbiology*
  • Case-Control Studies
  • Catheterization / adverse effects
  • Drug Utilization / standards
  • Escherichia coli / enzymology*
  • Escherichia coli / isolation & purification
  • Escherichia coli Infections / epidemiology*
  • Escherichia coli Infections / microbiology*
  • Escherichia coli Proteins / biosynthesis*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • beta-Lactam Resistance
  • beta-Lactamases / biosynthesis*

Substances

  • Anti-Bacterial Agents
  • Escherichia coli Proteins
  • beta-Lactamases